
Join to View Full Profile
11 Nevins StSuite 303Brighton, MA 02135
Phone+1 617-787-8181
Dr. Chudnovsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Illinois College of Medicine at ChicagoFellowship, Andrology (Male Infertility and Sexual Dysfunction), 2006 - 2007
University at BuffaloResidency, Urology, 2002 - 2006
University at Buffalo School of MedicineInternship, Transitional Year, 2001 - 2002
Boston University School of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2007 - 2025
IL State Medical License 2006 - 2014
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012
Publications & Presentations
PubMed
- 1 citationsPhase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.Sarit E Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B Johnston
Clinical Lymphoma, Myeloma & Leukemia. 2025-11-01 - A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies.Dejan Juric, Daniel Anderson, Afshin Dowlati, Jordi Rodon, Iwona Lugowska
Cancer Research Communications. 2025-11-01 - Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized...Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski
Targeted Oncology. 2023-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









